Myriad Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Aryeh Jason, was filed 20 Jun 2012.
Myriad Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at Myriad Pharmaceuticals, Inc. as filed with SEC (Form 4). The past year has been quiet: not a single insider filing for Myriad Pharmaceuticals, Inc. The previous disclosure was published on 25 January 2013.
The full history, which starts in 2009, counts 37 purchases against 4 sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Since the insiders bought
- -96.7%Entry US$2.43 · Close at T+365 US$0.08
- -97.4%Entry US$2.47 · Close at T+365 US$0.06
- -29.1%Entry US$3.81 · Close at T+365 US$2.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
· cache
- 7,500 shares@ US$1.07Common StockSEC:0001181431-13-004917:0
- 7,500 shares@ US$1.18Common StockSEC:0001181431-13-004917:1
- 7,500 shares@ US$1.65Common StockSEC:0001181431-13-004917:2
- 7,500 shares@ US$2.55Common StockSEC:0001181431-13-004917:3
- 2,500 shares@ US$0.95Common StockSEC:0001181431-13-004917:4
- 42,000 shares@ US$2.38Common Stock, $.01 par value (the "Common Stock")SEC:0001325447-12-000040:0
- 35,000 shares@ US$2.37Common Stock, $.01 par value (the "Common Stock")SEC:0001325447-12-000038:0
- 693 shares@ US$2.34Common StockSEC:0001181431-12-052192:0
- 20,000 shares0Common StockSEC:0001181431-12-041377:0
- 3,000 shares@ US$2.29Common StockSEC:0001181431-12-037400:0Canonical exit: 16 Sept 2012 (T+90)
- 4,000 shares@ US$2.36Common StockSEC:0001181431-12-037045:0Canonical exit: 12 Sept 2012 (T+90)
- 1,025 shares@ US$2.35Common StockSEC:0001181431-12-037045:1Canonical exit: 13 Sept 2012 (T+90)
- 1,116 shares@ US$2.40Common StockSEC:0001181431-12-035832:0Canonical exit: 5 Sept 2012 (T+90)
- 4,020 shares@ US$2.47Common StockSEC:0001181431-12-033828:0Canonical exit: 28 Aug 2012 (T+90)
- 10,133 shares@ US$2.35Common StockSEC:0001181431-12-033828:1Canonical exit: 29 Aug 2012 (T+90)
- 1,000 shares@ US$2.47Common StockSEC:0001181431-12-032855:0Canonical exit: 21 Aug 2012 (T+90)
- 153 shares@ US$2.47Common StockSEC:0001181431-12-032855:1Canonical exit: 23 Aug 2012 (T+90)
- 12,000 shares@ US$2.51Common StockSEC:0001181431-12-032050:0Canonical exit: 19 Aug 2012 (T+90)
- 262 shares@ US$2.46Common StockSEC:0001181431-12-032050:1Canonical exit: 20 Aug 2012 (T+90)
- 3,832 shares@ US$2.61Common StockSEC:0001181431-12-031431:0Canonical exit: 15 Aug 2012 (T+90)
- 7,168 shares@ US$2.60Common StockSEC:0001181431-12-031431:1Canonical exit: 16 Aug 2012 (T+90)
- 8,930 shares@ US$2.74Common StockSEC:0001181431-12-030718:0Canonical exit: 13 Aug 2012 (T+90)
- 27,700 shares@ US$2.74Common StockSEC:0001181431-12-030718:1Canonical exit: 14 Aug 2012 (T+90)
- 2,000 shares@ US$5.00Common StockSEC:0001181431-12-018636:0
- 9,500 shares@ US$5.00Common StockSEC:0001181431-12-004949:0
25 of 68 declarations
About Myriad Pharmaceuticals, Inc.
Myriad Pharmaceuticals, Inc. is a company focused on developing genetic tests and treatments for serious diseases. It is listed on NASDAQ under the ticker MYGN.
